MannKind Corporation


Taking a Page Out of David Shaw’s Investment Book: MannKind Corporation (MNKD), Valeant Pharmaceuticals Intl Inc (VRX), Gilead Sciences, Inc. (GILD)

David E. Shaw, quant genius and hedge fund manager billionaire extraordinaire founded DE Shaw as a sharp mathematical models-meets-algorithms dual-powered firm.

Company Update (NASDAQ:MNKD): MannKind Corporation Announces Q4 and Full Year 2016 Results

MannKind Corporation (NASDAQ:MNKD) reported financial results for the fourth quarter and full year ended December 31, 2016. Key results include: Total revenue for …

Stock Update (NASDAQ:MNKD): MannKind Corporation and Charles Mattocks Announce “REVERSED”-America’s First Docu-Series Tackling Diabetes

MannKind Corporation (NASDAQ:MNKD) and Bella & Elle Media LLC announce MannKind’s sponsorship of “Reversed,” a production series aimed at educating the show’s participants …

Stock Update (NASDAQ:MNKD): MannKind Corporation Announces Launch of New Titration Pack and Field Force Expansion to Accelerate Afrezza Growth

MannKind Corporation (NASDAQ:MNKD) announced the launch of a new Titration Pack containing 60 — 4 unit cartridges, 60 — 8 unit cartridges and …

Stock Update (NASDAQ:MNKD): MannKind Corporation Announces Key Addition to Its Executive Management Ranks

MannKind Corporation (NASDAQ:MNKD) announced that Stuart A. Tross, Ph.

Company Update (NASDAQ:MNKD): MannKind Corporation Receives $1 Million Milestone From RLS

MannKind Corporation (NASDAQ:MNKD) announced the confirmation that following the completion of initial formulation studies it received a $1 million milestone payment from Receptor Life Sciences, …

J.P. Morgan Bearish on MannKind Corporation (MNKD) In Light of Recent Agreement With Sanofi

MannKind Corporation (NASDAQ:MNKD) shares are on a close to 43% climb following the biotech firm’s announcement of an agreement reached with Sanofi on …

Stock Update (NASDAQ:MNKD): Securities Class Action Against MannKind Corporation Dismissed

MannKind Corporation (NASDAQ:MNKD) announced that the United States District Court for the Central District of California has dismissed the class action that was …

Piper Jaffray Provides 2H16 Outlook for MannKind Corporation (MNKD)

Piper Jaffray remains skeptical about relaunch strategies and their impact on Afrezza’s prescription numbers.

Piper Jaffray Remains Bearish on MannKind Corporation (MNKD) Amid 2Q Update; Sees 90% Downside for the Stock

MannKind Corporation (NASDAQ:MNKD) just reported second-quarter results. Recently, MNKD has begun to distribute to major wholesalers its pipeline drug Afrezza, a fast-acting inhalant …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts